CSMO 2014 :提高中央型肝癌治愈率的策略

2014-07-15 中国医学科学院肿瘤医院肝胆外科 吴健雄 医学论坛网

在7月4日的第八届中国肿瘤内科大会上,中国医学科学院肿瘤医院肝胆外科的吴健雄教授作了题为”提高中央型肝癌治愈率的策略“的主题报告。 自1891年lucke首先报道肝癌的外科治疗,肝癌肝切除技术快速发展,各种新的治疗方法不断涌现,目前已经建立了以外科为主导的综合治疗模式,大大提高了原发性肝癌的治疗效果。然而,对于一些中央型高危部位肿瘤,由于临近或侵犯肝内重要管道结构,手术切除率低,安全性差,复发率

在7月4日的第八届中国肿瘤内科大会上,中国医学科学院肿瘤医院肝胆外科的吴健雄教授作了题为”提高中央型肝癌治愈率的策略“的主题报告。

自1891年lucke首先报道肝癌的外科治疗,肝癌肝切除技术快速发展,各种新的治疗方法不断涌现,目前已经建立了以外科为主导的综合治疗模式,大大提高了原发性肝癌的治疗效果。然而,对于一些中央型高危部位肿瘤,由于临近或侵犯肝内重要管道结构,手术切除率低,安全性差,复发率高,仍然是目前肝癌治疗的难点。中国医学科学院肿瘤医院腹部外科肝癌研究组自2006年开展中央型肝癌综合治疗的临床研究,通过改进手术方式,提高切除率,保证安全性,强化综合理念,合理安排现有治疗手段,在实践中总结与创新,开拓了中央性肝癌治疗的新理念、新思路及新模式。

提高中央型肝癌治愈率的三大措施

目前,肝癌已经建立了以外科为主导的综合治疗,对于中央型肝癌,我们认为,提高治愈率首先要提高其切除率,施行规范的综合治疗,加强个体化治疗。三个方面相辅相成,缺一不可。

努力提高肝癌切除率

提高切除率的意义也是回答为何要努力提高切除率的问题,有研究提示,肝切除术后5年生存率30-70%,而不可切除肝癌的生存期较短:中位生存时间仅11-20月。手术切除能够有效祛除病灶,准确病理定性,术中及术后均能为辅助治疗创造条件,提高生活质量,延长总体生存。

影响切除率的三大主要原因:发现晚、肝硬化重,重要脏器功能差、中央型肝癌切除率低:个人技术、综合实力、先进设备。

提高切除率、保证安全性始终是肝脏外科医师的中心任务,提高切除率需从多方面努力。需要做到以下几点:

合理的围手术期治疗,快速康复外科理念的应用,力求微创技术,强化综合意识;

小切口做“大事”—(微创安全),大切口做“小事”—(精雕细琢);

革新手术方式:变复杂为简易,由扩切转雕琢;从粗犷至精确,活用微创理念;

肝区域选择性适时血流阻断技术。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2024436, encodeId=7df6202443686, content=<a href='/topic/show?id=6179220e1f2' target=_blank style='color:#2F92EE;'>#中央型肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22071, encryptionId=6179220e1f2, topicName=中央型肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Aug 03 11:16:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024728, encodeId=e1472024e2845, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri May 22 02:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642818, encodeId=9d331642818aa, content=<a href='/topic/show?id=5f99220e07f' target=_blank style='color:#2F92EE;'>#中央型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22070, encryptionId=5f99220e07f, topicName=中央型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6723029976, createdName=huagfeg, createdTime=Thu Apr 09 16:16:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988734, encodeId=e0811988e34c3, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Fri Jun 19 21:16:00 CST 2015, time=2015-06-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2024436, encodeId=7df6202443686, content=<a href='/topic/show?id=6179220e1f2' target=_blank style='color:#2F92EE;'>#中央型肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22071, encryptionId=6179220e1f2, topicName=中央型肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Aug 03 11:16:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024728, encodeId=e1472024e2845, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri May 22 02:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642818, encodeId=9d331642818aa, content=<a href='/topic/show?id=5f99220e07f' target=_blank style='color:#2F92EE;'>#中央型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22070, encryptionId=5f99220e07f, topicName=中央型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6723029976, createdName=huagfeg, createdTime=Thu Apr 09 16:16:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988734, encodeId=e0811988e34c3, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Fri Jun 19 21:16:00 CST 2015, time=2015-06-19, status=1, ipAttribution=)]
    2015-05-22 liuhuangbo
  3. [GetPortalCommentsPageByObjectIdResponse(id=2024436, encodeId=7df6202443686, content=<a href='/topic/show?id=6179220e1f2' target=_blank style='color:#2F92EE;'>#中央型肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22071, encryptionId=6179220e1f2, topicName=中央型肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Aug 03 11:16:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024728, encodeId=e1472024e2845, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri May 22 02:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642818, encodeId=9d331642818aa, content=<a href='/topic/show?id=5f99220e07f' target=_blank style='color:#2F92EE;'>#中央型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22070, encryptionId=5f99220e07f, topicName=中央型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6723029976, createdName=huagfeg, createdTime=Thu Apr 09 16:16:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988734, encodeId=e0811988e34c3, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Fri Jun 19 21:16:00 CST 2015, time=2015-06-19, status=1, ipAttribution=)]
    2015-04-09 huagfeg
  4. [GetPortalCommentsPageByObjectIdResponse(id=2024436, encodeId=7df6202443686, content=<a href='/topic/show?id=6179220e1f2' target=_blank style='color:#2F92EE;'>#中央型肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22071, encryptionId=6179220e1f2, topicName=中央型肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Aug 03 11:16:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024728, encodeId=e1472024e2845, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Fri May 22 02:16:00 CST 2015, time=2015-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642818, encodeId=9d331642818aa, content=<a href='/topic/show?id=5f99220e07f' target=_blank style='color:#2F92EE;'>#中央型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22070, encryptionId=5f99220e07f, topicName=中央型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6723029976, createdName=huagfeg, createdTime=Thu Apr 09 16:16:00 CST 2015, time=2015-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988734, encodeId=e0811988e34c3, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Fri Jun 19 21:16:00 CST 2015, time=2015-06-19, status=1, ipAttribution=)]
    2015-06-19 cenghis